Some toughts after the CC

New Post Public Reply Private Reply Replies (0) Message Board
TechGuru
316
I wanted to share my thoughts sometime after the CC as time itself provides some clearer answers.

We desperately needed a deal and we got one. The best one ? No, I am sure there are better and worse alternatives; but we got what we could. I don’t think CYDY is or was in a condition to make demands. We needed help and one gets it from whomever.

We have a contract that, theoretically will protect us from miss-behavior form Vyera (if any). But the important point here is that we need to keep on going … and this allows us to do just that.

If one does not like it there is no good reason to go bananas (as some have done), either get out (today would be a good day to do so), or appreciate that, what was negotiated could be just a (very) little piece of the pie, potentially a large one. This is JUST HIV for USA for Pete’s sake. This deal will give credibility to CDY in the face of potential international partners, if not now, when FDA says that we have a drug and we start selling Lero.

We just survived to fight another day. And this will come.

Without extending too much and going to the details there is not much to say as the appendix will show us “the devil”. However, 50% of “gross profit margin” is not a bad deal at all (maybe a larger company would had negotiated for 15%-20%), some of you say that there are no details, true. Let’s wait for them before jumping up and down. If done in good faith the end result will be close to 50% of what is left once COGS is taken out (for both parties). The lawyers I am sure have thought about this one and nobody will be taking advantage of the other.

Which bring us to sales, what I see is a “hungry” company with loses in the last couple of years. They will be happy to receive something they can actually sell and start profiting (their fate is tied to ours). Hopefully they will be able to ramp-up their sales team rapidly need will be.

The critical point here is PRICING. This is very complicated in light of potential Oncology (and Mono) implications. I wouldn’t’ like to be in the pants of those that have to make a decision that will have implications in the order of 100’s of millions. Too high of a price, less sales and lower potential profit. Too low, less profit. The thing is I don’t believe neither company currently has enough data to make a reasonable good decision. So it will be what it will be. I only hope CYDY has a big saying in this.

We have become so used to extraordinary news that MS didn’t even register in the radar. Does anybody remember Dr. Dennis Berger carefully explaining to a very anxious crowd his progress in MS and the fact that a P2 protocol (similar to Biogen’s Tysabri) is ready? I don’t want to insult anybody’s intelligence by saying this is BIG news … but, what do we do?? Go bananas and start crying foul foul !!!.

We got a deal, maybe with the Devil, but as my dad used to tell me: “one can make deals with the devil provided one knows is the Devil”. This is for a small portion of (hopefully) a very large cake, so, let’s be grateful we can continue walking to find our pot of gold at the end of the rainbow.

BTW: 87 Million (milestones) for a company of a MC of 140 Million should mean $0.6 share in improved valuation so “normally” we should be hovering close to $1. Normally I said

Everybody have a great Holiday Season and a very Happy Christmas !!!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BiomX Advances Phage-Based Therapy for Diabetic Foot Infections

Updated Category News Views 128

BiomX's Innovative Approach to Diabetic Foot Infections BiomX Inc. (NYSE: PHGE), a pioneering clinical-stage company specializing in natural and engineered phage therapies, has announced exciting developments regarding its novel treatment for diabetic foot infections (DFI). Following supportive feedback from the U.S. Food and Drug Administration (FDA), BiomX is gearing up...

Continue Reading
Moneta's Remote Brain Therapy Beats In-Person Results

Updated Category News Views 35

Innovation in Brain Health Comes via Telephone, Not Apps Sometimes, it's astonishing to see how a simple idea can disrupt an entire industry. Take Moneta Health, for example. Their approach is giving the whole world a wake-up call, quite literally. They're not flaunting fancy new apps or diving deep into virtual reality. Instead, they're harnessing the power of a simple...

Continue Reading
Nextensa Boosts Liquidity with Successful Sale of Shares

Updated Category News Views 167

Nextensa Strengthens Financial Position with Recent Share Sale Nextensa NV/SA, widely recognized as a mixed property investor and developer, has recently achieved a notable financial milestone. The company announced the successful completion of a strategic share sale involving Wereldhave N.V., which has significantly enhanced its liquidity position and set the stage for...

Continue Reading
Taylor Farms Group Unveils Comprehensive Impact Initiatives

Updated Category News Views 140

Taylor Farms Group Unveils Comprehensive Impact Initiatives Highlights Achievements and Continuous Efforts to Nourish Both People and Planet Taylor Farms has recently published its latest Impact Report, showcasing innovative initiatives related to products, processes, people, and community involvement. As a prominent supplier of ready-to-eat salads and healthy fresh...

Continue Reading
Compass, Inc. to Share Annual Results and Insights Soon

Updated Category News Views 130

Compass, Inc. Plans Upcoming Financial Results Announcement Compass, Inc., also known as Compass International Holdings (NYSE: COMP), a leader in global real estate services, is preparing to announce its financial results for the fourth quarter and full-year 2025. This important update will take place after the market closes on February 26, 2026. Investors and...

Continue Reading